Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 8;30(5):4844-4860.
doi: 10.3390/curroncol30050365.

Cryoablation and Immunotherapy: An Enthralling Synergy for Cancer Treatment

Affiliations

Cryoablation and Immunotherapy: An Enthralling Synergy for Cancer Treatment

Zain Al Abidine Medlej et al. Curr Oncol. .

Abstract

As less invasive options for surgical tumor removal, minimally invasive ablative techniques have gained popularity. Several solid tumors are being treated with cryoablation, a non-heat-based ablation technique. Cryoablation data in comparison over time demonstrates better tumor response and faster recovery. Combining cryosurgery with other cancer therapies has been explored to improve the cancer-killing process. Cryoablation with the combination of immunotherapy, results in a robust and efficient attack on the cancer cells. This article focuses on investigating the ability of cryosurgery to create a strong antitumor response when combined with immunologic agents resulting in a synergetic effect. To achieve this objective, we combined cryosurgery with immunotherapy using Nivolumab and lpilimumab. Five clinical cases of lymph node, lung cancer, bone, and lung metastasis were followed and analyzed. In this series of patients, percutaneous cryoablation and addressing immunity agents were technically feasible. In the follow-ups, there appeared to be no radiological evidence of new tumor development.

Keywords: cancer; cryosurgery; immunity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
CT scan image executed.
Figure 2
Figure 2
CT scan (left) and Pet-CT (right) images of hypermetabolic left pulmonary hilar tumor from a female SCC patient.
Figure 3
Figure 3
CT scan image showing hypermetabolic left pulmonary hilar tumor from male SCC patient.
Figure 4
Figure 4
CT scan (left) and Pet- CT (right) images from April 2021 with evidence of bone metastases. The arrows indicate the tumor’s location.
Figure 5
Figure 5
The probe inside the tumor, cryoablation date: 11 August 2021 at the cryosurgery center.
Figure 6
Figure 6
CT scan images indicate the presence of bilateral pulmonary and mediastinal lymph node metastases close to the esophagus. The arrow indicates the tumor’s location.
Figure 7
Figure 7
PETCT (left) and CT scan (right) images of the lymph node were performed after cryotherapy of the 35-year-old female patient.
Figure 8
Figure 8
CT scan image, 6 months after treatment with cryotherapy and immunotherapy of the female patient with SCC.
Figure 9
Figure 9
CT scan image, 6 months after treatment with cryotherapy and immunotherapy of the male patient with SCC.
Figure 10
Figure 10
PET-CT (left) and Ct scan(right) images after cryotherapy in the patient with lung cancer accompanied by bone metastases.
Figure 11
Figure 11
CT scan images after cryotherapy in the patient with bilateral lung metastasis and mediastinal lymph nodes. The arrow indicates where the tumor was located.

Similar articles

Cited by

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics. Cancer Surg. 2018;68:7–30. - PubMed
    1. Steeg P.S. Targeting Metastasis. Nat. Rev. Cancer. 2016;16:201–218. doi: 10.1038/nrc.2016.25. - DOI - PMC - PubMed
    1. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–489. doi: 10.1038/nature10673. - DOI - PMC - PubMed
    1. Sharma P., Wagner K., Wolchok J.D., Allison J.P. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat. Rev. Cancer. 2011;11:805–812. doi: 10.1038/nrc3153. - DOI - PMC - PubMed
    1. Barnestein R., Galland L., Kalfeist L., Ghiringhelli F., Ladoire S., Limagne E. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. Oncoimmunology. 2022;11:2120676. doi: 10.1080/2162402X.2022.2120676. - DOI - PMC - PubMed